Bio-Techne Corporation (NASDAQ: TECH) announced on March 12 that it has completed the acquisition of Zephyrus Biosciences. Zephyrus Biosciences will be integrated into the Protein Platforms Division of Bio-Techne.
Zephyrus Biosciences is a life science research tool firm developing and commercializing its single-cell Western blotting (scWestern) system. The company raised $1.5 million in seed funding led by Bay Area investor group Life Sciences Angels, and also included Mission Bay Capital, The Angel Forum, the Stanford StartX Fund, and several individual investors with deep life sciences experience.
In addition to the seed funding, Zephyrus said it has been awarded a $350,000 Phase I Small Business Innovation Research grant from the National Institutes of Health as well as $10,000 from the UC Bakar Fellows Program.
Zephyrus spun out from Dr. Amy Herr’s laboratory at UC Berkeley in 2013 and is affiliated with QB3, CLSI/BayBio, StartX Med, a Stanford-affiliated nonprofit technology accelerator, and SkyDeck at UC Berkeley. Zephyrus is also a graduate of Steve Blank’s Lean Launchpad for Life Sciences and Healthcare, an NSF iCorps program from UCSF.
Read the full story here.